A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells [neuroblastoma vaccine] After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma (CHESAT).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Neuroblastoma vaccine (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms CHESAT
Most Recent Events
- 10 Mar 2021 Biomarkers information updated
- 13 Apr 2012 Planned end date changed from 1 Jul 2027 to 1 Jul 2028 as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.